Light Therapy Emerges as Non-Invasive Pain Relief Option for Animals

Groundbreaking research into light-induced analgesia (LIA) shows promise for veterinary medicine and potentially human applications.

Jan. 31, 2026 at 4:39pm by Ben Kaplan

Got story updates? Submit your updates here. ›

A recent study published in Nature Communications has revealed a novel approach to pain management using light therapy. The research focuses on a protein called TRAAK, found in pain-sensing neurons, which acts as a 'dampener' to reduce the transmission of pain signals to the brain. Exposing rodents to near-violet light (380nm) was shown to activate this protein, effectively silencing the pain pathway and providing significant and lasting pain relief, even in cases of chronic pain. While the same light sensitivity is not present in humans, the discovery of TRAAK's role in pain signaling has sparked excitement about developing drugs that can mimic the effect of light, potentially leading to more effective and targeted pain therapies with fewer side effects.

Why it matters

This breakthrough in light-based pain relief offers a non-invasive and potentially more precise alternative to traditional pharmacological interventions, which often come with undesirable side effects. The immediate impact is likely to be felt in veterinary medicine, where the research highlights the applicability of LIA to a range of animals, including those often challenging to treat. With 78% of veterinarians actively seeking non-pharmacological pain management options, LIA perfectly addresses this need.

The details

The core of LIA lies in the TRAAK protein, which acts as a 'dampener' to reduce the transmission of pain signals to the brain. Scientists at the CNRS discovered that illuminating rodents with near-violet light (380nm) activates this protein, effectively silencing the pain pathway. Remarkably, just minutes of light exposure provided significant and lasting pain relief, even in models of chronic pain. This non-invasive approach offers a potential solution to the challenges faced in veterinary medicine, where conventional drugs are often metabolized differently, making dosage tricky.

  • The research was recently published in Nature Communications.

The players

TRAAK

A protein found in pain-sensing neurons that acts as a 'dampener,' reducing the transmission of pain signals to the brain.

Dr. Emily Carter

A neuroscientist specializing in pain management at the University of California, San Francisco.

Dr. David Lee

A pharmaceutical researcher at Pfizer.

Got photos? Submit your photos here. ›

What they’re saying

“The beauty of this approach is its precision. Conventional painkillers flood the system, impacting various bodily functions. LIA, in theory, targets only the pain receptors, minimizing systemic side effects.”

— Dr. Emily Carter, neuroscientist specializing in pain management

“We're looking at a potential paradigm shift in pain management. Instead of blocking pain signals, we're aiming to amplify the body's natural pain-dampening mechanisms. This could lead to more effective and targeted therapies with fewer side effects.”

— Dr. David Lee, pharmaceutical researcher

What’s next

Researchers are now focused on developing drugs that can mimic the effect of light, activating TRAAK without the need for external illumination. Several pharmaceutical companies are already investing in research exploring these avenues, with early-stage clinical trials anticipated within the next 3-5 years.

The takeaway

This breakthrough in light-based pain relief offers a promising non-invasive and potentially more precise alternative to traditional pharmacological interventions, particularly in veterinary medicine where it could address the need for effective and safe pain management options. While direct light-based therapy may not be feasible for humans, the discovery of TRAAK's role in pain signaling has opened up new avenues for developing targeted pain-relieving therapies with fewer side effects.